Cargando…

A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology

Chronic kidney disease (CKD) patients and more so CKD patients treated with renin–angiotensin–aldosterone system inhibitors (RAASi) are prone to experience hyperkalaemia, a condition associated with an increased risk of death. This represents a true dilemma in daily practice since RAASi are the corn...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rossignol, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392417/ https://www.ncbi.nlm.nih.gov/pubmed/30837805 http://dx.doi.org/10.1093/eurheartj/suy032

Ejemplares similares

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments
por: Zannad, Faiez, et al.
Publicado: (2019)

Potassium homoeostasis and pathophysiology of hyperkalaemia
por: Kjeldsen, Keld Per, et al.
Publicado: (2019)

Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners
por: Abensur Vuillaume, Laure, et al.
Publicado: (2020)

New treatments for hyperkalaemia: clinical use in cardiology
por: Vijayakumar, Shilpa, et al.
Publicado: (2019)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023)

New frontiers for management of hyperkalaemia: the emergence of novel agents
por: Nassif, Michael E, et al.
Publicado: (2019)

Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
por: Trevisan, Marco, et al.
Publicado: (2018)

Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs
por: Uijtendaal, Esther V., et al.
Publicado: (2011)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia
por: Gorriz, José Luis, et al.
Publicado: (2021)

Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review
por: Rossignol, Patrick, et al.
Publicado: (2019)

Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…
por: Carrero, Juan Jesus, et al.
Publicado: (2023)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program
por: Rossignol, Patrick, et al.
Publicado: (2021)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Surreptitious hyperkalaemia and its complications
por: Morgenstern, Tilo, et al.
Publicado: (2009)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
por: Humphrey, Toby, et al.
Publicado: (2021)

Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care
por: Provenzano, Michele, et al.
Publicado: (2018)

Suxamethonium-chloride: Hyperkalaemia: case report
Publicado: (2021)

Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
por: Mudge, David W, et al.
Publicado: (2011)

Nafamostat: Off-label use and hyperkalaemia: case report
Publicado: (2020)

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Optimizing Therapies in Heart Failure: The Role of Potassium Binders
por: Scicchitano, Pietro, et al.
Publicado: (2022)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
por: Slawik, Jonathan, et al.
Publicado: (2020)

Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure
por: Maggioni, Aldo P., et al.
Publicado: (2021)

Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

Rapidly changing ECG in hyperkalaemia after succinylcholine
por: Plane, Anne-Flore, et al.
Publicado: (2019)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Clinical nephrology
por: Brenner, Barry M., 1937-
Publicado: (1987)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Hypoglycaemia due to insulin therapy for the management of hyperkalaemia in hospitalised adults: A scoping review
por: Chothia, Mogamat-Yazied, et al.
Publicado: (2022)

Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia
por: Vijayakumar, Shilpa, et al.
Publicado: (2019)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Current treatment and unmet needs of hyperkalaemia in the emergency department
por: Rafique, Zubaid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h27gofj1mdjb9d6p1dsuajg2n1